Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

Overview of attention for article published in Circulation, November 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

So far, Altmetric has seen 5 public wall posts from 3 users.

Résultats de l’étude DAPA-HF évaluant les effets de la dapagliflozine sur les symptômes, la fonction et la qualité de vie des…

#CircOnTheRun episode featuring Dr Mikhail Kosiborod

In #DAPA-HF, the SGLT2 inhibitor dapagliflozin improved symptoms, physical function, and quality of life in patients with #HFrEF.

DAPA-HF -dapagliflozin improved symptoms, physical function and quality of life in patients with HFREF #CircAHA19 #AHA19 #AHAJou…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity, including 1 additional Facebook posts.